TY - JOUR ID - 28109 TI - Two-Week Combination Chemotherapy with Gemcitabine, High-Dose Folinic Acid and 5 Fluorouracil (GEMFUFOL) as First-Line Treatment of Metastatic Biliary Tract Cancers JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 Y1 - 2013 PY - 2013 VL - 14 IS - 9 SP - 5263 EP - 5267 KW - Metastatic biliary tract cancer KW - Gemcitabine KW - 5-fluorouracil KW - high-dose folinic acid DO - N2 - Background: The aim of this study was to evaluate the efficacy and tolerability of a gemcitabine, 5-fluorouraciland leucovorin (GEMFUFOL) chemotherapy regimen as first line treatment of metastatic biliary tract cancer.Materials and Methods: All patients received folinic acid 400 mg/m2 on day 1, 5-fluorouracil bolus 400 mg/m2 on day 1, IV infusion of 5-fluorouracil 2400 mg/m2 over 46 hours, and gemcitabine 1250 mg/m2 on day 1.Results: A total of 29 patients with metastatic biliary tract cancer received GEMFUFOL regimen as the firstlinetreatment. The mean follow-up was 22.1 months (95%CI, 12.5-31.8). One patient (3.4%) achieved completeresponse, 5 (17.2%) had partial response, and 4 (13.8%) had stable disease. The median progression-free survivalwas 3.3 months (95%CI, 2.9-3.7), and the median overall survival was 8.8 months (95%CI, 3.5-14). The 1-yearand 2-year survival rates were 58.6% and 30%, respectively. Grade 3 and 4 toxicity included neutropenia in4 patients (13.7%), thrombocytopenia in 2 (6.8%), anemia in 2 (6.8%), and alopecia in 1 (3.4%). Two patients(6.8%) developed febrile neutropenia. A dose reduction was achieved in 8 patients (27.6%) while 5 patientshad extended-interval dosage (17.2%) for toxicity. Conclusions: The GEMFUFOL chemotherapy regimen wasgenerally efficacious and tolerable as a first-line treatment of metastatic biliary tract cancer. UR - https://journal.waocp.org/article_28109.html L1 - https://journal.waocp.org/article_28109_8c3e1948190c9509cb242f6fd2f9e809.pdf ER -